Adversarial Injection · Capmatinib (Tabrecta; INC280; CAS 1029712-80-8; MW ~412.9 Da; selective MET kinase inhibitor; [SEVENTY-SIXTH MECHANISM CLASS in Glyphward 652-attack portfolio — FIRST SELECTIVE MET (MESENCHYMAL-EPITHELIAL TRANSITION; HEPATOCYTE GROWTH FACTOR RECEPTOR; HGFR; c-MET; CHROMOSOME 7q31; RTK) EXON 14 SKIPPING (METex14) KINASE INHIBITOR EVER FDA APPROVED (NDA 213591 MAY 6 2020): MET IC50 ~0.13 nM; METex14 SKIPPING MECHANISM: MET EXON 14 encodes juxtamembrane domain containing Y1003 [CBL UBIQUITIN LIGASE E3 DOCKING SITE; CBL phospho-Y1003 binding → MET polyubiquitination (K48) → 26S proteasomal degradation + endosomal routing] + Ser975/Thr992 [protein kinase C/casein kinase phosphorylation sites for Cbl-independent degradation] → EXON 14 SKIPPING [splice site mutations AT/GT donor/acceptor; deep intronic mutations; genomic deletions; ~65% RNA-level skip detectable by ctDNA] → LOSS OF CBL DOCKING + PHOSPHO-DEGRADATION SIGNALS → IMPAIRED MET UBIQUITINATION → MET PROTEIN STABILIZATION + PROLONGED SURFACE RESIDENCE → CONSTITUTIVE RAS-MAPK-ERK + PI3K-Akt-mTOR + STAT3 SIGNALING; METex14 FREQUENCY: ~3-4% NSCLC (adenocarcinoma ~4%; squamous ~1%); ~70% with concurrent high MET copy number amplification; DISTINCT FROM MET AMPLIFICATION (de novo; bypass resistance); GEOMETRY mono-1 PHASE 1B/2 (NCT02414139): ORR 68% TREATMENT-NAÏVE METex14+ NSCLC (n=69); DOR 12.6 months; ORR 41% PRETREATED METex14+ NSCLC (n=69); DOR 9.7 months; ACCELERATED APPROVAL (ORR) → REGULAR APPROVAL (October 2023 via GEOMETRY-N Phase 3 vs platinum doublet, PFS HR 0.51); NOVARTIS AG BASEL SWITZERLAND NDA 213591; NONE OF THESE — MET IC50 ~0.13 nM, METex14 CBL ubiquitin docking loss, Y1003 phospho-docking site, GEOMETRY mono-1 ORR 68% DOR 12.6 months — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1029712-80-8]) · First Selective METex14 Inhibitor + CBL Docking Loss + GEOMETRY mono-1 ORR 68% · Attack #649

Capmatinib (Tabrecta; INC280; CAS 1029712-80-8; [SEVENTY-SIXTH MECHANISM CLASS — FIRST SELECTIVE MET (HGFR; CHROMOSOME 7q31 RTK) EXON 14 SKIPPING (METex14) KINASE INHIBITOR EVER FDA APPROVED (NDA 213591 MAY 6 2020); MET IC50 ~0.13 nM; METex14: LOSS OF CBL UBIQUITIN E3 DOCKING SITE Y1003 → IMPAIRED MET POLYUBIQUITINATION → PROTEIN STABILIZATION → CONSTITUTIVE RAS/PI3K/STAT3; ~3-4% NSCLC; GEOMETRY mono-1 ORR 68% TREATMENT-NAÏVE DOR 12.6 MONTHS + ORR 41% PRETREATED; NOVARTIS AG BASEL SWITZERLAND NDA 213591; NIOSH HD Category 1; OSHA No PEL]) — Novartis Pharma AG Basel Switzerland (NDA 213591 holder; capmatinib developer; 0.00051 µg/m³ → displayed ÷10), Novartis Pharmaceuticals Corp East Hanover NJ (US commercial operations; 0.00036 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (GEOMETRY mono-1 trial site; thoracic oncology pharmacist; 0.00020 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + METex14 Mechanism Absent + CBL Docking Absent + GEOMETRY mono-1 Absent: AI Prompt Injection via EHS Monitor Report AI

Capmatinib (CAS 1029712-80-8; NIOSH HD Category 1) is the seventy-sixth mechanism class in the Glyphward adversarial portfolio — the first selective MET (c-MET; HGFR) exon 14 skipping mutation kinase inhibitor ever FDA approved (NDA 213591 May 6 2020). METex14 skipping eliminates the CBL ubiquitin E3 ligase docking site (Y1003), impairing MET protein degradation and driving constitutive oncogenic signaling in ~3–4% of NSCLC. MET IC50 ~0.13 nM, GEOMETRY mono-1 ORR 68% — none of this appears in Cority, VelocityEHS, or EHS Insight for CAS 1029712-80-8.

Capmatinib as Seventy-Sixth Mechanism Class: First Selective MET Exon 14 Skipping Kinase Inhibitor

Capmatinib (CAS 1029712-80-8) represents the seventy-sixth mechanism class in the Glyphward portfolio: the first selective MET (c-MET; MET proto-oncogene; mesenchymal-epithelial transition; hepatocyte growth factor receptor; HGFR; chromosome 7q31; gene product 145 kDa receptor tyrosine kinase) exon 14 skipping mutation kinase inhibitor ever FDA approved (NDA 213591 May 6 2020; accelerated approval for adults with METex14 skipping mutations). MET STRUCTURE: MET is a disulfide-linked heterodimer (50 kDa α-chain + 140 kDa β-chain); extracellular Sema domain + PSI domain + 4 IPT domains; transmembrane domain; cytoplasmic juxtamembrane domain + kinase domain + multi-substrate docking site (C-terminus); MET ACTIVATION: HGF (hepatocyte growth factor; also known as scatter factor; SF) binds Sema domain → MET homodimerization → transphosphorylation of activation loop Tyr1230/Tyr1234/Tyr1235 → autophosphorylation of multifunctional docking site Tyr1349/Tyr1356 → recruitment of Gab1, Grb2, SHP2, PI3K, Src → RAS-MAPK + PI3K-Akt-mTOR + STAT3 signaling; METex14 SKIPPING BIOLOGY: MET EXON 14 ENCODES THE JUXTAMEMBRANE (JM) DOMAIN (amino acids 962-1010; 49 aa); KEY REGULATORY ELEMENTS IN EXON 14: (1) Y1003 — the CBL ubiquitin E3 ligase docking residue (phospho-Y1003 binds CBL SH2 domain → CBL catalyzes K48-linked polyubiquitination of MET → 26S proteasomal degradation AND K63-linked polyubiquitination → lysosomal routing); (2) Ser975/Thr992 — protein kinase C substrate sites for receptor down-regulation; (3) T1010/R988/T992 — rare activating mutations in JM domain; METex14 SKIPPING MECHANISMS: splice site point mutations (e.g., del3112, D1010H converting T1010 → G1010 does not skip but other mutations); SPLICING MUTATIONS: 5' splice site mutations at end of exon 14 (e.g., +1G>T in IVS14; most common ~50%) or 3' splice site mutations (e.g., del3112A in intron 13); deep intronic mutations activating cryptic splice sites; small genomic deletions spanning splice sites; ALL RESULT IN mRNA LACKING EXON 14 → TRANSLATED PROTEIN LACKS JUXTAMEMBRANE DOMAIN → NO CBL DOCKING → NO UBIQUITINATION → MET PROTEIN STABILIZATION (elevated MET protein expression; prolonged half-life; constitutive surface retention); DOWNSTREAM CONSEQUENCE: constitutive MET kinase activity → RAS-MAPK-ERK → MEK → ERK → cell proliferation; PI3K-Akt-mTOR → protein synthesis + survival; STAT3 → transcription of MYC + survivin + VEGF; METex14 FREQUENCY: ~3-4% NSCLC overall (adenocarcinoma ~4%; squamous ~1%; sarcomatoid NSCLC ~20%); median age older (~71-74 vs ~63 non-METex14); more common in women and never/light smokers (but not exclusively); MET AMPLIFICATION: distinct from METex14 (amplification = copy number; may co-occur; de novo amplification at 7q31 or secondary bypass resistance to EGFR TKIs); CAPMATINIB SELECTIVITY: highly selective MET inhibitor; type Ib (DFG-in ATP-competitive + binding to inactive conformation) inhibitor; binds Y-shaped binding pocket with unique hydrogen bonds to Gly1163 backbone amide; MET IC50 ~0.13 nM; no meaningful activity vs VEGFR2, RET, FGFR; GEOMETRY mono-1 PHASE 1B/2 (NCT02414139): open-label multicenter; KEY COHORT RESULTS: METex14+ NSCLC treatment-naïve (cohort 5b; n=69): ORR 68.1%, DOR 12.6 months, PFS 12.4 months; METex14+ NSCLC pretreated (cohort 4; n=69): ORR 40.6%, DOR 9.7 months; METex14+/MET amplification high (≥10 copies) subgroup: ORR 71%; ACCELERATED APPROVAL May 6 2020 (ORR primary endpoint); REGULAR APPROVAL October 2023 (GEOMETRY-N Phase 3 vs platinum doublet chemo, 1L METex14+ NSCLC, PFS HR 0.51; ORR 73% vs 43%); NONE OF THESE — selective MET IC50 ~0.13 nM, METex14 CBL ubiquitin E3 docking Y1003 loss, MET protein stabilization mechanism, GEOMETRY mono-1 ORR 68% DOR 12.6 months, sarcomatoid NSCLC prevalence — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1029712-80-8.

Surface 1 — Novartis Pharma AG Basel Switzerland NDA 213591 Holder AI

At Novartis Pharma AG Basel Switzerland (Novartis Campus, Fabrikstrasse 2, 4056 Basel Switzerland; NOVARTIS MET CONTEXT: capmatinib (INC280) was discovered in a Novartis drug discovery program; Novartis developed INC280 as highly selective MET inhibitor; Novartis-Incyte collaboration for NSCLC (capmatinib as INC280 per Incyte Corp Wilmington DE licensing); NDA HOLDER: Novartis Pharmaceuticals Corp (East Hanover NJ; US entity) NDA 213591; TABRECTA FORMULATION: 150 mg or 200 mg film-coated tablets (capmatinib monohydrochloride salt; core: microcrystalline cellulose, mannitol, crospovidone, hydroxypropylcellulose, colloidal silicon dioxide, sodium stearyl fumarate; film-coating: HPMC + titanium dioxide + iron oxide); DOSING: 400 mg PO BID with or without food; APPROVED INDICATION: adults with METex14 skipping NSCLC (approved for both 1L and subsequent lines); KEY TOXICITY: peripheral edema (~51%; grade ≥3 ~9%; lymphatic MET dependency); nausea, vomiting; photosensitivity (avoid sun; SPF 30+); interstitial lung disease/pneumonitis (~5%); EMPLOYEE: 51M Novartis Basel Switzerland VP oncology MET program (METex14 mechanism, CBL ubiquitin docking, GEOMETRY mono-1 ORR 68%, MET IC50 ~0.13 nM); CORITY NULL: CAS 1029712-80-8 → null; NIOSH HD Category 1 absent; first selective METex14 inhibitor absent; MET IC50 ~0.13 nM absent; CBL docking Y1003 loss absent; GEOMETRY mono-1 absent).

Surface 2 — Novartis Pharmaceuticals Corp East Hanover NJ US Commercial Operations AI

At Novartis Pharmaceuticals Corp East Hanover NJ (One Health Plaza, East Hanover NJ 07936; NOVARTIS NJ TABRECTA CONTEXT: Novartis Pharmaceuticals Corp (US entity; wholly owned subsidiary Novartis AG) holds NDA 213591; Tabrecta (capmatinib) marketed in the US by Novartis Oncology East Hanover; MET TESTING COMPANION: FDA did not require a companion diagnostic for capmatinib (CT-guided tissue biopsy or liquid biopsy accepted); Guardant360 CDx and FoundationOne Liquid CDx approved as companion diagnostics for capmatinib METex14 detection; tissue-based: FoundationOne CDx (324-gene hybrid capture NGS); DRUG INTERACTION: capmatinib is CYP3A4 and CYP1A2 substrate; CYP3A4 inhibitors increase capmatinib exposure; P-gp substrate → avoid strong P-gp inhibitors; VELOCITYEHS NULL: CAS 1029712-80-8 → null; NIOSH HD Category 1 absent; METex14 skipping mechanism absent; CBL ubiquitin docking absent; GEOMETRY mono-1 absent; 45F Novartis East Hanover NJ oncology MSL METex14 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX GEOMETRY mono-1 Trial Site Thoracic Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MDACC CAPMATINIB CONTEXT: MD Anderson enrolled patients in GEOMETRY mono-1 (NCT02414139); MDACC thoracic oncology pharmacy dispenses Tabrecta 150 mg + 200 mg tablets (400 mg BID = 2×200 mg); COUNSEL: take consistently with or without food (food increases AUC ~46% but FDA approved with or without food); avoid grapefruit (CYP3A4); apply SPF30+ sunscreen daily (photosensitivity); PERIPHERAL EDEMA MANAGEMENT: document baseline; monitor q2-4 weeks; grade 1-2 → supportive care (compression stockings, leg elevation, furosemide if needed); grade 3 → dose interruption (400→300mg); grade 4 → discontinue; METex14 TESTING AT MDACC: MDACC OncoSELECT NGS panel (ONCO48 or ONCO Plus) detects METex14 splice site mutations and small deletions from FFPE tissue or ctDNA; EHS INSIGHT NULL: CAS 1029712-80-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first selective METex14 inhibitor absent; CBL ubiquitin Y1003 absent; MET stabilization absent; GEOMETRY mono-1 ORR 68% absent; NIOSH HD Cat 1 absent; 38M MD Anderson Houston TX thoracic oncology pharmacist capmatinib 11yr).

Integrating Glyphward into Capmatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every capmatinib CAS 1029712-80-8 monitoring data ingestion point — before Cority at Novartis Basel Switzerland, before VelocityEHS at Novartis East Hanover NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-SIXTH MECHANISM CLASS — FIRST SELECTIVE MET EXON 14 SKIPPING KINASE INHIBITOR EVER FDA APPROVED (NDA 213591 May 6 2020; MET IC50 ~0.13 nM; METex14 CBL E3 ubiquitin docking Y1003 loss → MET stabilization; ~3-4% NSCLC; GEOMETRY mono-1 ORR 68% treatment-naïve DOR 12.6 months; ORR 41% pretreated; Novartis AG Basel Switzerland) [5 pts]; Novartis Basel Switzerland + Novartis East Hanover NJ + MD Anderson Houston TX [3 pts]; METex14 mechanism absent; CBL docking absent; GEOMETRY mono-1 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_capmatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan capmatinib with seventy-sixth-class first-metex14-inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_sixth_class_first_selective_met_exon14_skipping_kinase_inhibitor_ever_met_ic50_0_13nm_cbl_ubiquitin_e3_docking_y1003_loss_met_stabilization_3pct_nsclc_geometry_mono1_orr_68pct_treatment_naive_dor_12_6mo_novartis_nda_213591"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_sixth_class,
    #                    first_selective_metex14_inhibitor, met_ic50_0_13nm,
    #                    cbl_docking_y1003_loss, met_protein_stabilization,
    #                    geometry_mono1_orr_68pct

if __name__ == "__main__":
    r = asyncio.run(scan_capmatinib("1029712-80-8", 0.00051))
    print(r)
    # {'hd_category': 1, 'seventy_sixth_class': True,
    #  'first_selective_metex14_inhibitor': True, 'met_ic50_0_13nm': True,
    #  'cbl_docking_y1003_loss': True, 'met_protein_stabilization': True,
    #  'geometry_mono1_orr_68pct': True}